Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label flexible-dose pilot study evaluating the efficacy, safety, and
tolerability of Pristiq (desvenlafaxine) in outpatient subjects diagnosed with Generalized
Anxiety Disorder (GAD) with or without comorbidities that are secondary to the GAD. Primary
trial objective is to evaluate the efficacy of Pristiq (desvenlafaxine) SNRI treatment 50 to
100 mg once daily in the treatment of GAD with or without comorbidities. Secondary trial
objective is to determine whether or not treatment outcome in GAD is related to changes in
cortical prefrontal activity of norepinephrine.